Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 9/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31082315 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL31324803 | 0.90 | KDM4E (0.81) | KDM4EALDH1A1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL5666716 | 0.90 | KDM4E (0.81) | KDM4EALDH1A1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL23625923 | 0.89 | KDM4E (0.79) | KDM4EALDH1A1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL30952930 | 0.89 | KDM4E (0.79) | KDM4EALDH1A1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL30952885 | 0.89 | KDM4E (0.79) | KDM4EALDH1A1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL30041634 | 0.85 | KDM4E (0.73) | KDM4EALDH1A1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL24961374 | 0.85 | KDM4E (0.73) | KDM4EALDH1A1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL24824152 | 0.84 | ALDH1A1 (0.72) | KDM4EALDH1A1MAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL24823394 | 0.84 | ALDH1A1 (0.72) | KDM4EALDH1A1MAPTSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4037687-B1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | MOLECULAR SKIN THERAPEUTICS INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12281123-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | MOLECULAR SKIN THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| CN-114615984-B | Benzoxazinone compounds as dual KLK5/7 inhibitors | 分子皮肤治疗公司 | 2025-02-07 | — | — | CN | disclosed |
| US-20240067658-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | ML Bio Solutions Inc. | 2024-02-29 | — | — | US | disclosed |
| US-20240067658-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | ML Bio Solutions Inc. | 2024-02-29 | — | — | US | disclosed |
| US-20240067658-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | ML Bio Solutions Inc. | 2024-02-29 | — | — | US | disclosed |
| WO-2023165438-A1 | TRICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 浙江海正药业股份有限公司 | 2023-09-07 | — | — | WO | disclosed |
| US-11643420-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | MOLECULAR SKIN THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643420-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | MOLECULAR SKIN THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643420-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | MOLECULAR SKIN THERAPEUTICS, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-20120046282-A1 | METHODS AND COMPOUNDS FOR ANTIMICROBIAL INTERVENTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-02-23 | — | — | US | disclosed |
| US-20100022509-A1 | Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-28 | — | — | US | disclosed |
| WO-2009151561-A2 | METHODS AND COMPOUNDS FOR ANTIMICROBIAL INTERVENTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-12-17 | — | — | WO | disclosed |
| WO-2008036139-A2 | INHIBITORS OF MSHC AND HOMOLOGS THEREOF, AND METHODS OF IDENTIFYING SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-27 | — | — | WO | disclosed |
| EP-1117659-B1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | WYETH CORP (US) | 2003-12-03 | — | — | EP | disclosed |
| US-6288082-B1 | COMPOUNDS SUCH AS 6,7-DIETHOXY-4-(INDAN-5-YLAMINO) -QUINOLINE-3-CARBONITRILE USED AS ANTINEOPLASTIC AGENTS AND IN THE TREATMENT OF POLYCYCSTIC KIDNEY DISEASE | AMERICAN CYANAMID COMPANY | 2001-09-11 | — | — | US | disclosed |
| EP-1117659-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018761-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| US-4011323-A | ANTIOBESITY AND ANTIDIABETIC | SANDOZ, INC. (US) | 1977-03-08 | — | — | US | disclosed |
| US-3931179-A | ANTIOBESITY | SANDOZ INC. (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022509-A1 | Inhibitors of MshC and Homologs Thereof, and Methods of Identifying Same | ICMT, TST, OGA | KDM4E 3951/4885ALDH1A1 1325/4885MAPT 2336/4885 |
| US-20120046282-A1 | METHODS AND COMPOUNDS FOR ANTIMICROBIAL INTERVENTION | FDFT1, COASY, KAT5 | KDM4E 1419/4885ALDH1A1 4179/4885MAPT 3404/4885 |
| US-12281123-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | KLK5, KLK1, KLK2 | KDM4E 377/4885ALDH1A1 1224/4885MAPT 2106/4885 |
| US-11643420-B2 | Benzoxazinone compounds as KLK5/7 dual inhibitors | KLK5, KLK1, KLK2 | KDM4E 377/4885ALDH1A1 1224/4885MAPT 2106/4885 |
| US-20240067658-A1 | BENZOXAZINONE COMPOUNDS AS KLK5/7 DUAL INHIBITORS | KLK5, KLK1, KLK2 | KDM4E 377/4885ALDH1A1 1224/4885MAPT 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.